Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial.
Cytokinetics, Incorporated
Unlock to Claim this listing
Add / Modify Company
3.4
Overall Excellence Rating
Industry
HealthcareCategory
Biotech & PharmaceuticalsESG/Ethical Impact
Cytokinetics’ dedication to environmental stewardship is palpable through its conscientious integration of sustainable practices, spanning energy-efficient technologies, eco-conscious supply chain decisions, and waste reduction strategies, thereby amplifying its efforts to mitigate its ecological footprint and engender a more sustainable future through tangible actions that underscore its commitment to fostering a healthier planet for current and future generations.Cytokinetics stands as a beacon of positive social impact, fervently driven by its unwavering mission to improve patient well-being and global health, channeling its pioneering therapies toward addressing unmet medical needs, while actively engaging in patient support programs, community partnerships, and health education initiatives, catalyzing a ripple effect of empowerment, inclusivity, and hope within the communities it serves.At the nucleus of its corporate ethos resides Cytokinetics’ unwavering dedication to exemplary governance practices, rooted in principles of transparency, accountability, and ethical conduct that permeate its operational landscape, reinforced by a diverse and experienced board of directors, stringent compliance protocols, and an organizational culture steeped in integrity, underpinning its commitment to aligning stakeholder interests and corporate values.Cytokinetics’ financial sustainability is indelibly intertwined with its broader ESG imperatives, as its financial growth is intrinsically linked to its capacity to develop and deliver innovative healthcare solutions that resonate with patients, healthcare professionals, and investors who recognize the value of responsible innovation, ethical leadership, and sustainable business practices.Cytokinetics’ relentless pursuit of research excellence and innovation emerges as a guiding force underpinning its ESG sustainability, epitomized by its unwavering commitment to pushing the boundaries of therapeutic development, addressing complex medical challenges, and advancing the frontiers of medical science, all while steadfastly adhering to the highest ethical standards, research integrity, and a patient-centric ethos that animates its role as a vanguard of transformative healthcare solutions.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us

Awards Received
2023
Revenues
$95,000,000.00
Website Traffic
Employee Rating
3.5
Customer Rating
3.7
Company Size
100-1000
ESG Risk Rating
3